
Sorrento Therapeutics
Sorrento Therapeutics: A San Diego-based biopharmaceutical firm specializing in therapeutic antibodies for various diseases.

Sorrento Therapeutics: A San Diego-based biopharmaceutical firm specializing in therapeutic antibodies for various diseases.
Founded in San Diego, Sorrento Therapeutics is a biopharmaceutical company dedicated to developing human therapeutic antibodies aimed at treating cancer, inflammation, metabolic, and infectious diseases. The company's core mission is to innovate and deliver effective therapies that address unmet medical needs, enhancing patient outcomes and quality of life. Sorrento Therapeutics focuses on a broad market, targeting significant health challenges through its diverse pipeline of antibody-based treatments.
Notable figures affiliated with Sorrento Therapeutics include prominent scientists and industry leaders who contribute to its research and development efforts. The company has attracted substantial investment from various stakeholders, underscoring confidence in its potential. Key achievements include the development of multiple promising therapeutic candidates and advancements in antibody technology. Sorrento Therapeutics' impact is marked by its commitment to pioneering treatments that could transform the landscape of biopharmaceutical therapies.
Companies similar to Sorrento Therapeutics include Sutro Biopharma, Sorriso Pharmaceuticals, Poseida Therapeutics and Crinetics Pharmaceuticals.
Sorrento Therapeutics was founded in 2006.
Sorrento Therapeutics' headquarters is located in San Diego, CA, US.
Sorrento Therapeutics' most recent funding round was for $25M (USD) in October 2019.
As of Oct 9, 2019, Sorrento Therapeutics has disclosed funding of $264.4M (USD). Undisclosed round amounts are excluded.
Sorrento Therapeutics has 949 employees as of Feb 6, 2024.

Crinetics Pharmaceuticals
crinetics.com